Creating new treatments for infections that resist antibiotics
Official title: Development of Therapeutic Products for Antibacterial Resistant Infections
Funded at Crestone, INC. · NIH-11250890 · Data updated 2026-11-12
This study is looking for new treatments to help fight infections from tough bacteria, like Clostridioides difficile, and if you're interested, you might have a chance to join a trial testing these new options to see if they're safe and work well.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Crestone, INC. NIH-funded |
| Lab location | 1 site (Boulder, United States) |
| Project start | September 9, 2019 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $573,467 |
| NIH project number | 75N93019C00056-P00013-9999-1 |
| Project ID | NIH-11250890 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals with infections caused by antibiotic-resistant bacteria, particularly those with Clostridioides difficile.
✕Less likely to help
Patients with infections that are not caused by antibiotic-resistant bacteria may not benefit from this research.
What this research studies
This research focuses on developing new therapeutic products to combat infections caused by antibiotic-resistant bacteria, including Clostridioides difficile. The approach involves optimizing potential drug candidates and conducting preclinical studies to ensure their safety and effectiveness. Patients may have the opportunity to participate in a Phase I clinical trial, which is the first step in testing new treatments in humans. The research aims to address the growing threat of antibiotic resistance, which poses significant health risks.
Why it matters
Potential benefit: If successful, this research could lead to effective new treatments for patients suffering from antibiotic-resistant infections.
How similar studies have gone: Other research has shown promise in developing treatments for antibiotic-resistant infections, indicating that this approach has potential for success.
Where this research is happening
-
Crestone, INC.
Boulder, United States Active
Researchers
- Principal investigator: Oschner, Urs — Crestone, INC.
- Study coordinator: Oschner, Urs
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.